Valuation: Monopar Therapeutics Inc.

Market Cap 779M 675M 631M 576M 1.09B 74.33B 1.1B 7.4B 2.9B 37.19B 2.93B 2.86B 124B P/E 2026 *
-50.4x
P/E 2027 * -33.6x
Enterprise Value 661M 572M 535M 489M 921M 63.03B 935M 6.27B 2.46B 31.53B 2.48B 2.43B 105B EV / Sales 2026 *
-
EV / Sales 2027 * 42.1x
Free-Float
76.58%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week-3.31%
Current month+5.71%
1 month+10.85%
3 months+74.82%
6 months+92.86%
Current year+75.41%
1 week 113.54
Extreme 113.54
124.82
1 month 97.93
Extreme 97.93
124.82
Current year 50.07
Extreme 50.07
124.82
1 year 29.18
Extreme 29.18
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 30/11/2014
Director of Finance/CFO 54 02/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 30/11/2014
Chairman 73 30/11/2014
Director/Board Member 84 31/03/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-3.31%+265.48%+3,126.48% 779M
-0.22%+3.85%+6.76%+16.75% 50.03B
-1.87%+4.95%+485.13%+577.03% 44.36B
+1.28%+12.26%+25.14%+83.43% 40.82B
+0.29%+6.38%+34.79%+10.42% 39.83B
+0.85%+10.32%+21.22%+47.64% 32.51B
-0.41%+3.98% - - 16.85B
+0.02%+4.87%+34.09%+125.96% 16.81B
-0.03%+1.74%+5.67%+21.56% 14.05B
+0.34%+18.86%+86.85%+29.75% 13.22B
Average -0.21%+263.60%+107.24%+448.78% 26.93B
Weighted average by Cap. -0.04%+294.52%+106.85%+146.81%

Financials

2026 *2027 *
Net sales - 15.84M 13.71M 12.82M 11.71M 22.08M 1.51B 22.42M 150M 58.98M 756M 59.48M 58.18M 2.52B
Net income -20.16M -17.45M -16.31M -14.91M -28.1M -1.92B -28.54M -191M -75.07M -962M -75.7M -74.05M -3.2B -35.74M -30.94M -28.92M -26.43M -49.8M -3.41B -50.58M -339M -133M -1.71B -134M -131M -5.68B
Net Debt -119M -103M -95.94M -87.68M -165M -11.31B -168M -1.13B -441M -5.66B -445M -435M -18.84B -112M -97.25M -90.9M -83.08M -157M -10.71B -159M -1.07B -418M -5.36B -422M -413M -17.85B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
11/08/26 US$114.29 -1.77% 111,662
10/08/26 US$116.35 -2.40% 280,348
07/08/26 US$119.21 -0.83% 223,298
06/08/26 US$120.21 +0.82% 285,799
05/08/26 US$119.23 +0.65% 182,731
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
116.35USD
Average target price
116.85USD
Spread / Average Target
+0.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock